Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Cancers | Free Full-Text | Targeting DNA Damage Repair Mechanisms in Pancreas Cancer
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
Olaparib in Pancreas Cancer | Polo Trial | One oncologist breaks it down - YouTube
JNCCN study evaluates cost-effectiveness of o | EurekAlert!
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
POLO: Olaparib as maintenance treatment for metastatic pancreatic cancer - YouTube
Olaparib now approved for advanced pancreatic cancer - UChicago Medicine
FORCE Blog | New PARP Inhibitor Approval for Pancreatic Cancer
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
Dr. Antonio Calles 🫁🚭 on Twitter: "LBA4 POLO trial: olaparib maintenance in germline BRCA mutant pancreatic adenocarcinoma. Nice data but... PFS as primary endpoint comparing active drug vs no treatment is not
Predicting Benefit From Olaparib Maintenance in Metastatic Pancreatic Cancer: The POLO Trial - Cancer Therapy Advisor
Asco 2019 – Polo reveals an overall survival hole | Evaluate
Dr Amol Akhade on Twitter: "19 vs 19.2 . POLO . Metastatic pancrease ca. Once again Placebo arm has longer OS than Olaparib. I really appreciate the positive spin off by medical
Cancer Trial Results
ASCO GI 2021: Results From the Phase 3 POLO Trial
Olaparib maintenance therapy improves PFS in BRCA-mutated metastatic pancreatic cancer | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
Pancreatic Cancer - ASCO GI 2021 Highlights - Module - 2021 ASCO GI - Oncology - Clinical Care Options
LYNPARZA® (olaparib) Efficacy for Metastatic Pancreatic Cancer
ASCO GI 2021: Results From the Phase 3 POLO Trial
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial) | SpringerLink
Cancer Trial Results
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM
Cancer Trial Results
